Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Report 2026

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Overview

• Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment market size has reached to $9.44 billion in 2025 • Expected to grow to $14.27 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Surge In Rise In Smoking Drives Cases Fueling The Growth Of The Market Due To Increasing Smoking-Related Respiratory Disease Burden • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market?

Asthma-chronic obstructive pulmonary disease (COPD) overlap treatment refers to the therapeutic approach for patients exhibiting features of both asthma and COPD, aiming to control symptoms and reduce exacerbations. It typically involves a combination of inhaled corticosteroids, bronchodilators, and lifestyle modifications tailored to improve lung function and quality of life. The treatment strategy focuses on managing airway inflammation, relieving obstruction, and preventing disease progression. The main drug classes of asthma-chronic obstructive pulmonary disease (COPD) overlap treatment include triple therapy, dual therapy, biologics, and systemic therapies. Triple therapy refers to a combination treatment approach that integrates multiple pharmacological agents to manage both asthma and chronic obstructive pulmonary disease symptoms. These treatments are used across treatment use cases including exacerbation prevention in asthma chronic obstructive pulmonary disease overlap phenotypes, severe asthma with fixed airflow limitation, chronic obstructive pulmonary disease with eosinophilic inflammation, post hospital discharge optimization, and comorbidity driven management, and are administered through inhalation and oral routes. They are prescribed for pediatric, adult, and geriatric patient groups, and are used by several end users such as retail pharmacy channel, hospitals, pulmonology clinics, primary care centers, and other end users.

What Is The Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Growth Forecast?

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market size is expected to see strong growth in the next few years.It will grow to $14.27 billion by 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to expansion of biologics in respiratory disease management, increasing adoption of digital respiratory monitoring devices, rising demand for personalized treatment regimens, growth in home based chronic disease management, advancement in targeted anti inflammatory therapies.Major trends in the forecast period include personalized precision therapy for asthma-COPD overlap phenotypes, digital inhaler adherence monitoring and connected respiratory care, rise of biologic-based treatment for eosinophilic airway inflammation, integration of remote patient monitoring in chronic respiratory disease management, shift toward combination inhalation therapies for optimized airway control.

Global Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Segmentation

1) By Drug Class: Triple Therapy, Dual Therapy, Biologics, Systemic Therapies 2) By Treatment Use Case: Exacerbation Prevention In Asthma Chronic Obstructive Pulmonary Disease Overlap Phenotypes, Severe Asthma With Fixed Airflow Limitation, Chronic Obstructive Pulmonary Disease With Eosinophilic Inflammation, Post Hospital Discharge Optimization, Comorbidity Driven Management 3) By Route Of Administration: Inhalation, Oral 4) By Patient Age Group: Pediatric, Adult, Geriatric 5) By End User: Retail Pharmacy Channel, Hospitals, Pulmonology Clinics, Primary Care Centers, Other End Users Subsegments: 1) By Triple Therapy: Inhaled Corticosteroid Long Acting Beta Agonist Long Acting Muscarinic Antagonist Combinations, Fixed Dose Combination Inhalers, Maintenance Therapy Combinations 2) By Dual Therapy: Inhaled Corticosteroid Long Acting Beta Agonist Combinations, Long Acting Beta Agonist Long Acting Muscarinic Antagonist Combinations, Add On Bronchodilator Combinations 3) By Biologics: Interleukin Five Inhibitors, Interleukin Four And Interleukin Thirteen Pathway Inhibitors, Immunoglobulin E Targeting Therapies, Monoclonal Antibody Treatments 4) By Systemic Therapies: Oral Corticosteroids, Systemic Bronchodilators, Anti Inflammatory Agents, Immune Modulating Therapies

What Are The Drivers Of The Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market?

The rise in smoking-driven cases is expected to propel the growth of asthma chronic obstructive pulmonary disease (COPD) overlap treatment going forward.Smoking-driven cases refer to instances of respiratory diseases, such as asthma or COPD, that develop primarily due to tobacco smoking.Smoking-driven cases are growing due to the increasing number of people who use tobacco products, which causes lung inflammation, airway damage, and a higher risk of developing chronic respiratory diseases.Asthma-COPD overlap treatment addresses smoking-driven cases by providing targeted therapies that simultaneously manage the combined symptoms, airflow limitations, and lung damage caused by tobacco use, improving respiratory function and quality of life for patients with both asthma and COPD.For instance, in February 2026, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic obstructive pulmonary disease (COPD) contributed to 3.7 % of Australia’s total disease burden in 2024 and was the underlying cause of 7,437 deaths in 2023, equivalent to 28 deaths per 100,000 people, representing 4.1 % of all deaths.Therefore, the rise in smoking cases is expected to drive the growth of the asthma COPD overlap treatment market. The growing demand for precision medicine is expected to propel the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment industry going forward.Precision medicine refers to a medical approach that customizes treatment based on individual patient characteristics such as genetics, biomarkers, and disease phenotypes.The demand for precision medicine is rising due to advancements in biomarker identification and molecular diagnostics, which enable more accurate classification of respiratory conditions and targeted therapy selection.Precision medicine enables the identification of distinct patient phenotypes and underlying inflammatory pathways in asthma-chronic obstructive pulmonary disease (COPD) overlap, allowing healthcare providers to tailor targeted therapies, optimize treatment responses, minimize exacerbations, and improve overall disease management through individualized care strategies.For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, marking a substantial rise from the six approvals recorded in 2022.Therefore, growing demand for precision medicine is driving the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment industry. The increasing geriatric population is expected to propel the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment industry going forward.The geriatric population refers to individuals aged 65 years and above who are more susceptible to chronic health conditions due to age-related physiological changes.The geriatric population is rising due to increasing life expectancy and declining birth rates, leading to a higher proportion of older individuals in the overall population.Asthma-chronic obstructive pulmonary disease (COPD) overlap treatment enables improved management of respiratory symptoms in the geriatric population by providing tailored therapies that address complex disease patterns, reduce exacerbations, enhance lung function, and support better overall quality of life in older adults.For instance, in February 2025, according to the World Health Organization, a Switzerland‑based intergovernmental organization, the global population of people aged 60 years and older is rapidly increasing due to longer life expectancy and declining birth rates, with older adults projected to outnumber younger cohorts in many regions by 2030.Therefore, the growing geriatric population is driving the growth of the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment industry.

Key Players In The Global Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market

Major companies operating in the asthma-chronic obstructive pulmonary disease (copd) overlap treatment market are Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca PLC, GlaxoSmithKline plc, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Grifols S. A., Sun Pharmaceutical Industries Limited, Chiesi Farmaceutici S. p. A., Kyowa Kirin Co. Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Theravance Biopharma Inc., Orion Corporation

Regional Insights

North America was the largest region in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market?

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market consists of revenues earned by entities by providing services such as pulmonary function testing, medication management, inhaler therapy training, oxygen therapy, pulmonary rehabilitation, patient education, telemedicine consultations, follow-up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market also includes sales of inhalers, nebulizers, bronchodilators, corticosteroid inhalers, combination inhalers, dry powder inhalers, and metered-dose inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Industry?

The asthma-chronic obstructive pulmonary disease (copd) overlap treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the asthma-chronic obstructive pulmonary disease (copd) overlap treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Report 2026?

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market research report is one of a series of new reports from The Business Research Company that provides asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market statistics, including asthma-chronic obstructive pulmonary disease (COPD) overlap treatment industry global market size, regional shares, competitors with a asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market share, detailed asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market segments, market trends and opportunities, and any further data you may need to thrive in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment industry. This asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.